Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADRENAL: Intravenous hydrocortisone in critically ill patients with septic shock
2012-003158-10Phase 3Unknown
- Sponsor
- The George Institute for Global Health
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in septic shock comparing Hydrocortisone with Placebo (2 arms). Primary endpoint: All-cause mortality at 90 days. Status: unknown.
02
Drugs
hydrocortisone
03
Conditions
septic shock
Beyond the preview
Go deeper on 2012-003158-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003158-10.